Health Net Connections acquired by Hospital Services 

Strategic acquirers in the UK healthcare technology sector focus on a consistent set of value drivers: the size and quality of the installed base, recurring maintenance and support revenue, the security of any exclusive distribution or reseller agreements, and the depth of trust the business holds with clinicians and procurement teams. A supplier embedded in clinical workflow — where switching would disrupt patient care — is difficult to displace, which makes its revenue durable and its relationships defensible. For a distributor or platform acquirer, a business whose software already serves hundreds of hospitals and clinics adds installed reach that would take years to build, and it typically commands a stronger valuation in a competitive sell-side M&A process.

Most acquirers value a healthcare technology or medical device distribution business on a multiple of adjusted EBITDA, weighted heavily towards the proportion of revenue that is recurring — maintenance, support, and licence renewals — rather than one-off product sales. In UK mid-market M&A, where deal values typically sit in the £5m–£100m range, the quality of the underlying contracts matters as much as the headline number: the length and exclusivity of distribution agreements, customer concentration, and the renewal history of the installed base all move the multiple. A competitive sell-side process run by an experienced UK M&A advisor with healthcare sector knowledge is the most reliable way to establish a defensible valuation and prevent a first offer from anchoring the negotiation.

European healthcare groups value the UK as a large, single-payer-influenced market with established clinical relationships and regulatory standards that map closely to their own. For an acquisitive group building scale across the continent, a UK healthcare technology business offers direct market access, a ready installed base, and a software or imaging capability that complements existing device and consumables distribution. The acquisition of Health Net Connections by Hospital Services Ltd — part of Nasdaq Stockholm-listed Asker Healthcare Group — is a clear example: a bolt-on that extended a European group's ultrasound imaging and reporting offering into the UK, connecting installed hardware to the software that runs alongside it.

The outcome for customers and staff depends on the acquirer's integration approach and the strength of the terms negotiated. In healthcare technology, continuity of clinical service is central to the value being acquired, so strategic buyers usually retain implementation, support, and account teams — the people who hold the customer relationships that make the recurring revenue durable. In the Health Net Connections transaction, the business joined the HSL Group with access to a larger network and broader resources while its 250-plus healthcare customers continued to be supported. CapEQ works with founders to identify acquirers whose values and integration plans align with the legacy they want to protect, and to make cultural and operational fit a primary deal objective rather than an afterthought.

Timing is shaped by personal, business, and market factors together. On the personal side: clarity about what comes next, and whether leading the business still energises you. On the business side: a stable installed base, a healthy proportion of recurring maintenance and support revenue, secure distribution agreements, and a team that can support a transition without the founder on every call. On the market side: active consolidation and strategic acquirer interest in your part of healthcare technology. Founders who wait until an exclusive agreement is close to renewal, or until growth has plateaued, typically achieve weaker terms. The strongest UK healthtech exits are planned well ahead by founders who build with the end in mind.

Founders in this sector face a set of interconnected challenges. The first is concentration risk: where value rests on one or two exclusive distribution agreements or a small number of large NHS or private-hospital relationships, a buyer will scrutinise how secure and transferable those are. The second is the long procurement and sales cycle in UK healthcare, which can make revenue lumpy and harder to present cleanly. The third is regulatory and data-security diligence, which is more demanding when a business handles patient data. The fourth is key-person dependency, common in founder-led healthtech. Addressing these 12–18 months before a sale — documenting contracts, reducing founder dependency, and getting financials into clean, consistent form — gives an advisor the runway to position the business competitively.

A structured sell-side M&A process for a UK healthcare technology or medical device business typically runs between six and twelve months from formal advisor appointment to legal completion, and longer where the deal is cross-border or the diligence on data security, regulatory status, and distribution contracts is complex. Timelines are influenced by the readiness of financial and legal documentation, the number of credible acquirers engaged, and the pace of buyer due diligence. Where a business has existing relationships with potential acquirers, or receives an inbound approach, the timeline can compress — but that should not be mistaken for a reduction in process rigour. At CapEQ, we agree a realistic timetable with the founder at the outset and communicate milestones clearly throughout.

Choosing the right sell-side M&A advisor comes down to three things: sector-specific valuation fluency, a track record of completed transactions in healthcare or technology, and independence from conflicts of interest. A generalist adviser can run a process, but one who understands recurring-revenue quality, exclusive distribution agreements, and the specific universe of device and healthcare-technology acquirers will produce a materially different outcome. CapEQ is a Certified B Corporation — a B Corp certified M&A advisor, independently certified to prioritise client outcomes over deal income — and advised the shareholders of Health Net Connections on their sale to Hospital Services Ltd, part of Asker Healthcare Group. Partner-led engagement means the senior team you meet at the outset is the team that negotiates your completion.